Warwas M, Narczeuska B, Dobryszycka W
Arch Immunol Ther Exp (Warsz). 1977;25(2):235-42.
The authors observed changes in activity of leucine amino-peptidase (E.C. 3.4.1.1--LAP), gamma-glutamyl transpeptidase (F.C 2.3.2.2--GGTP) and Co++-activated acylase in blood serum of patients with ovarian carcinoma, with or without ascites, treated with Ledakrin (1-nitro-9-[3-dimethylaminopropylamino] acridine). It was stated that the activities of LAP and GGTP increased during the treatment and during tumor progression. The level of Co++-activated acylase increased only slightly during the treatment and therefore, the determination of this enzyme appeared to be of no use in monitoring the therapy of ovarian carcinoma.
作者观察了接受雷达克林(1-硝基-9-[3-二甲氨基丙基氨基]吖啶)治疗的有或无腹水的卵巢癌患者血清中亮氨酸氨基肽酶(E.C. 3.4.1.1-LAP)、γ-谷氨酰转肽酶(E.C 2.3.2.2-GGTP)和Co++激活的酰基转移酶活性的变化。结果表明,在治疗期间和肿瘤进展过程中,LAP和GGTP的活性增加。Co++激活的酰基转移酶水平在治疗期间仅略有增加,因此,测定该酶似乎对监测卵巢癌的治疗没有用处。